Prior to PSM, significant differences were observed between the sarcopenia group (SA group, n=106) and the non-sarcopenia group (Non-SA group, n=159) in several variables, including Eastern Cooperative Oncology Group performance status (ECOG PS), Child-Pugh class, prothrombin time, serum albumin, total bilirubin, tumor number, maximum tumor diameter, portal vein tumor thrombus, and extrahepatic metastasis (all P < 0.05). This evidence concerns the gene F2 and neoplasm.